BioMarin Pharmaceutical Inc. P/Operating CF

P/Operating CF of BMRN for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/Operating CF growth rates and interactive chart. A valuation metric that measures the price of a stock compared to its operating cash flow per share. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low P/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current P/Operating CF of BioMarin Pharmaceutical Inc. is 1450.54 (as of December 31, 2021)
  • P/Operating CF for the quarter ending March 31, 2022 was -312.25 (a -121.53% decrease compared to previous quarter)
  • Year-over-year quarterly P/Operating CF decreased by -269.43%
  • Annual P/Operating CF for 2021 was 1450.54 (a -222.45% decrease from previous year)
  • Annual P/Operating CF for 2020 was -1184.6 (a -548.74% decrease from previous year)
  • Annual P/Operating CF for 2019 was 263.99 (a -13.55% decrease from previous year)
Visit stockrow.com/BMRN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/Operating CF of BioMarin Pharmaceutical Inc.

Most recent P/Operating CFof BMRN including historical data for past 10 years.

Interactive Chart of P/Operating CF of BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. P/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -312.25
2021 1450.54 145.9 184.29 120.92 1450.54
2020 -1184.6 159.86 803.66 -1000.49 -1184.6
2019 263.99 172.32 -619.07 -290.57 263.99
2018 305.36 370.83 -490.65 -319.88 305.36
2017 1086.5 428.61 843.27 -188.46 1086.5
2016 -67848.34 -1496.61 -276.15 -77.71 -67848.34
2015 -254.59 -5945.44 -1688.89 -142.53 -254.59
2014 -553.39 -1239.77 -792.86 -370.7 -553.39
2013 -1077.14 -1070.51 -1215.48 -246.08 -1077.14
2012 493.69 346.23 -3461.8 -542.05 493.69
2011 -7634.35 403.87 222.87 -7634.35

Business Profile of BioMarin Pharmaceutical Inc.

Sector: Healthcare
Industry: Biotechnology
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.